Agenus reports 21.2-month median survival in Phase 1b BOT+BAL study for MSS metastatic colorectal cancer

PUBT · 2d ago
Agenus reports 21.2-month median survival in Phase 1b BOT+BAL study for MSS metastatic colorectal cancer
  • Agenus disclosed a peer-reviewed publication of mature Phase 1b results; earlier three-year efficacy data were previously presented at ESMO GI 2026.
  • The BOT-BAL regimen showed durable survival and tumor responses in heavily pretreated MSS metastatic colorectal cancer without active liver metastases.
  • Activity appeared in immunologically “cold” tumors, supporting the program’s immune-priming rationale beyond standard checkpoint-response markers.
  • Safety follow-up showed no new signals, supporting a lower-dose strategy aimed at reducing immune-mediated side effects.
  • Findings strengthen the case to test the combination earlier, including planned Phase 3 evaluation in curative-intent neoadjuvant colon cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608281007BIZWIRE_USPR_____20260828_BW879955) on August 28, 2026, and is solely responsible for the information contained therein.